Insmed Inc. (INSM)
Insmed (INSM) Lags on Q2 Earnings, Tops Sales, Reiterates View
Insmed (INSM) posts mixed second-quarter results. It reaches alignment with the FDA on the primary endpoint of a late-stage study that seeks to expand the label of Arikayce.
Compared to Estimates, Insmed (INSM) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for Insmed (INSM) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Insmed (INSM) Reports Q2 Loss, Tops Revenue Estimates
Insmed (INSM) came out with a quarterly loss of $1.94 per share versus the Zacks Consensus Estimate of a loss of $1.22. This compares to loss of $1.78 per share a year ago.
Insmed (INSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Biotech Stocks to Monitor Right Now
Last week, we profiled biotech exchange-traded fund (ETF) SPDR S&P Biotech ETF (XBI) amid a historically bullish month.
Insmed (INSM) Stock Soars 118% on Upbeat Lung Disease Drug Data
Data from a late-stage study shows that treatment with Insmed's (INSM) brensocatib reduced episodes of worsening disease symptoms in patients with bronchiectasis, a chronic lung condition.
Insmed Stock More Than Doubled in Value Tuesday—Here's Why
Insmed (INSM) shares more than doubled in value Tuesday after the biopharmaceutical company announced positive results in a late-stage study of its experimental drug to reduce symptoms in patients with a rare lung disease.
Insmed shares skyrocket on positive trial results for lung drug
Insmed Incorporated (NASDAQ:INSM) shares more than doubled after the company released positive results from its late-stage study of its experimental therapy brensocatib for a lung condition. The company said patients in the study with non-cystic fibrosis bronchiectasis who were dosed with brensocatib saw statistically significant reductions in the annualized rate of pulmonary exacerbations compared to placebo.
Insmed Strikes Gold With Phase 3 Bronchiectasis Win (Rating Upgrade)
Brensocatib, Insmed's DPP1 inhibitor, showed significant efficacy in the Phase 3 ASPEN study for treating NCFB. Insmed's financial position includes high R&D costs with a solid short-term liquidity ratio but substantial long-term debt. Peak revenue estimates for brensocatib range from $1-5 billion, with a reasonable midpoint of $3 billion expected.
Insmed Catapults 128% After Proving Its Theory In A 'Large, Untapped' Lung Disease Market
Insmed stock catapulted Tuesday after the biotech company experimental lung disease treatment succeeded in a final-phase study.
Why Is Insmed (INSM) Stock Up 134% Today?
Insmed (NASDAQ: INSM ) stock is rising higher on Tuesday after the company announced positive results from a Phase 3 clinical trial of brensocatib in patients with non-cystic fibrosis bronchiectasis. This saw brensocatib reach its primary endpoint of statistically significant reductions in the annualized rate of pulmonary exacerbations (PEs) versus placebo.
Insmed's stock rockets toward a 2-decade high after positive drug-trial data
Shares of Insmed Inc. skyrocketed Tuesday, after the biopharmaceutical company said it plans to file a New Drug Application for its treatment of non-cystic fibrosis bronchiectasis following positive Phase 3 trial results.
